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BACKGROUND: Lymph node metastasis is one of the most important adverse prognostic factors for pancreatic cancer. The aim of this
study was to identify novel lymphatic metastasis-associated markers and therapeutic targets for pancreatic cancer.
METHODS: DNA microarray study was carried out to identify genes differentially expressed between 17 pancreatic cancer tissues with
lymph node metastasis and 17 pancreatic cancer tissues without lymph node metastasis. The microarray results were validated by
real-time PCR. Immunohistochemistry and western blotting were used to examine the expression of farnesoid X receptor (FXR).
The function of FXR was studied by small interfering RNA and treatment with FXR antagonist guggulsterone and FXR agonist
GW4064.
RESULTS: Farnesoid X receptor overexpression in pancreatic cancer tissues with lymph node metastasis is associated with poor patient
survival. Small interfering RNA-mediated downregulation of FXR and guggulsterone-mediated FXR inhibition resulted in a marked
reduction in cell migration and invasion. In addition, downregulation of FXR reduced NF-kB activation and conditioned medium from
FXR siRNA-transfected cells showed reduced VEGF levels. Moreover, GW4064-mediated FXR activation increased cell migration
and invasion.
CONCLUSIONS: These findings indicated that FXR overexpression plays an important role in lymphatic metastasis of pancreatic cancer
and that downregulation of FXR is an effective approach for inhibition of pancreatic tumour progression.
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Pancreatic cancer is one of the most clinically aggressive
malignancies, with a 3-year survival rate of only 17% after surgical
resection of the primary tumour (Niederhuber et al, 1995). Poor
prognosis of pancreatic cancer is related with early metastasis to
regional lymph nodes (LNs) or liver, as the presence or absence of
LN metastasis is an important prognostic factor for patients with
pancreatic cancer (Mao et al, 1995; Maeda et al, 2007). However,
the mechanisms involved in LN metastasis of pancreatic cancer are
not fully understood. Therefore, identification of molecular marker
that might predict LN metastasis of pancreatic cancer is important
in selecting patients who would benefit from surgical treatment or
molecular targeting therapy.
The farnesoid X receptor (FXR) is a member of the nuclear
receptor superfamily of ligand-dependent transcription factors
that forms a heterodimer with the retinoid X receptor (Forman
et al, 1995; Seol et al, 1995). Farnesoid X receptor is highly
expressed in the liver, gut, kidney, and adrenal cortex, and
regulates a variety of genes with roles in bile acid homeostasis,
lipid, and glucose metabolism (Laffitte et al, 2000; Wang et al,
2008). In contrast, low levels of mRNA for FXR are present in a
variety of tissues, including heart, ovary, thymus, eye, spleen, and
testes (Otte et al, 2003; Bishop-Bailey et al, 2004). The roles of FXR
in these tissues are poorly understood, particularly within human
beings. Recently, FXR was reported to play a role in tumour
growth. Farnesoid X receptor-null mice spontaneously develop a
high incidence of liver tumours, including hepatocellular adeno-
ma, carcinoma, and hepatocholangiocellular carcinoma (Kim et al,
2007). In addition, FXR has recently been detected in breast cancer
tissue and breast cancer cell lines (Silva et al, 2006; Swales et al,
2006; Journe et al, 2008). The correlation between FXR expression
and tumour cell proliferation suggests that, in addition to the
involvement of FXR in cell survival and proliferation, this nuclear
receptor is involved in tumour invasiveness and metastasis (Journe
et al, 2009). Farnesoid X receptor is expressed in colorectal tumour
cells; however, it is not clear how bile acid-induced activation of
FXR triggers carcinogenesis or tumour metastasis (De Gottardi
et al, 2004).
In this study, we have characterised for the first time the role of
FXR in pancreatic cancer. These studies began with microarray
analyses of pancreatic cancers with LN metastasis vs those without
LN metastasis in tumours of the same size. One of the most
interesting candidate genes identified by this approach, FXR, was
selected for further investigation for its expression. We examined
the consequence of FXR siRNA, guggulsterone (GS), and GW4064
treatment on pancreatic cancer proliferation, migration, and
invasion.
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Clinical specimens
A total of 34 clinical pancreatic cancer tissues were obtained from
surgical resection collected at Samsung Medical Center. We
divided the samples into two groups according to the absence
(Group I) or presence (Group II) of LN metastasis, and the
clinicopathological characteristics of tumour stage and survival
dates of each group are summarised in Table 1.
The cancer stage of each case was classified according to the
tumour node metastasis (TNM) classification of the Union
International Contre le Cancer. Tumour node metastasis was
defined as size or direct extent of the primary tumour (T, 1–4) that
spreads to regional LNs (N, 0–3) and develops distant metastasis
(M, 0/1). Clinical follow-up was obtained from patient’s medical
record. Postoperative survival was measured from the day of
surgery to the death or censored last follow-up visit. The mean
patient survival in Group I without LN metastasis was 23.4±8.8
months, whereas the mean patient survival in Group II with LN
metastasis was 9.1±3.9 months. Most of the clinicopathological
characteristics of the two groups, except for LN metastasis, were
similar (i.e., surgical method, degree of differentiation of cancer,
tumour size, and the absence of distant metastasis).
Informed consent was obtained from all patients, and this study
was approved by the Samsung Medical Center Institutional Review
Board. Tissue samples were frozen in liquid nitrogen immediately
after surgical removal and were maintained at a temperature of
 801C until required for RNA extraction. From each frozen tissue
sample, serial sections were made and stained with haematoxylin
and eosin. A pathologist reviewed the serial slides and selected
representative sections that contained 470% of ductal adeno-
carcinomas in the tissue section volume.
Isolation of total RNA, gene expression array, and analysis
of microarray data
Human genome survey arrays (Applied Biosystems, Foster City,
CA, USA) were used to analyse the transcriptional profiles of the
pancreatic cancer tissue RNA samples. RNA isolation, sample
preparation, and array hybridisation were performed as described
previously (Kim et al, 2010a). The Applied Biosystems Expression
System software (Applied Biosystems) was used to extract assay
signals and assay signal-to-noise ratios from the microarray
images. The bad spots flagged by the software were removed from
the analysis. The raw data were exported to Excel files (Microsoft
Corporation, Redmond, WA, USA). The exported data files were
analysed using Avadis software (StrandGenomics, Bangalore,
India) and Arrayassist (Stratagene, La Jolla, CA, USA). The assay
signals of the remaining set of 99.5% of the genes were log-
transformed. To select differentially expressed genes, the remaining
sets of 99.5% of the genes were further filtered by means of a standard
expression array system signal-to-noise threshold (the signal-to-noise
ratio was 43 in at least one sample) and a flag threshold (o5000).
The filtered genes were normalised using the quantile normalisation
method. Significant genes were calculated using one-way analysis of
variance and the Tukey’s HSD test (Po0.05) and the fold-change
method. Statistical significances were adjusted by Benjamini–
Hochberg FDR multiple-testing correction. Fold change was calcu-
lated using the average of each group.
Real-time PCR for gene expression studies
Real-time analysis for target genes was performed as described
previously (Kim et al, 2010a).The TaqMan probe/primer sets were as
follows: LZIC, Hs00260696_m1; FXR, Hs00231968_m1; SCAMP1,
Hs00191607_m1; and SULT1E1, Hs00193690_m1. The target amount
was then divided by an endogenous reference amount (GAPDH;
Applied Biosystems) to obtain a normalised target value.
Reverse transcription–PCR analysis
Total RNA was prepared from cells using the RNeasy Mini kit
(Qiagen, Chatsworth, CA, USA) according to the manufacturer’s
instructions. Total RNA was converted into single-strand cDNA
with the Moloney murine leukaemia virus RT (Invitrogen, Grand
Island, NY, USA) with random hexamer primers. Primers
for human small heterodimer partner (SHP) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were as described in
Kim et al (2010b).
Tissue material and immunohistochemistry
Tissue sections on glass slides were deparaffinised with xylene,
rehydrated in serially diluted alcohol, and subsequently processed
in a microwave for 15min with Tris-EDTA (TE; pH 9) buffer for
antigen retrieval. After blocking of endogenous peroxidase with
3% H2O2, the sections were immersed in 3% goat serum diluted
with phosphate-buffered saline for 60min. The slides were then
incubated with a mouse monoclonal anti-human FXR antibody
(1:30 dilution; R&D Systems Co., Minneapolis, MN, USA) for
90min at room temperature. After rinsing three times with
distilled water containing 0.1% Tween-20, the tissue sections were
incubated with HRP-conjugated streptavidin for 20min at room
temperature. Slides were then washed, developed for 5min with
liquid 3,30-diaminobenzidine tetrahydrochloride, counterstained
with Meyer’s haematoxylin, dehydrated, and mounted with
Permount for histological examination. The results of immunos-
taining were recorded as an intensity score according to the
estimated staining proportion (no, 0; weak, o10%; moderate,
10B50%; and strong, 450%).
Cell lines and reagents
Human pancreatic cancer cell lines (MIA-PaCa2, PANC-1, AsPC-1,
Capan-1 and Capan-2), the HepG2 hepatoma cell line, and the
MCF-7 breast cancer cell line used in this study were obtained
from the American Type Culture Collection (Manassas, VA, USA).
GS, GW4064 and mitomycin C were purchased from Sigma
(St Louis, MO, USA).
Downregulation of FXR expression by siRNA
Cells were transfected with FXR sequence and control siRNA using
Lipofectamine RNAiMAX reagent (Invitrogen) according to the
manufacturer’s instructions. After transfection at a final concen-
tration of 30nM siRNA, cells were cultured for 72h. The sequence
Table 1 Clinicopathological characteristics
a
Characteristics Group I (LN ) Group II (LN+)
Age (years) 61±10.1 56.6±9.5
Gender
Male 11 9
Female 6 8
Pathological
T classification T3 T3
N classification N0 N1
Stage IIA IIB
Survival
Live 6 0
Dead 11 17
Postoperative survival (months) 23.4±8.8 9.1±3.9
Abbreviation: LN¼lymph node.
aThese patients were selected in a blinded manner.
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AAAUA-30) was synthesised and annealed by Invitrogen. The
control siRNA (scramble; 50-AAAGCGUCUGGAAAAGUCG-30)
from Invitrogen was used to evaluate the nonspecific effects on
transfection on gene expression.
Western blot analysis
Fifty micrograms of proteins were separated on NuPAGE Novex
Bis–Tris 4–12% gels (Invitrogen) and electroblotted onto
nitrocellulose membranes. Membranes were then incubated in
blocking solution (5% milk in 20mM Tris HCl, 150mM NaCl, and
0.1% Tween-20), followed by overnight incubation with a mouse
monoclonal anti-human FXR antibody (diluted 1:250; R&D
Systems). Peroxidase-labelled anti-mouse IgG antibody (1:10000;
Cell Signaling, Beverly, MA, USA) was used as a secondary
reagent. Bound peroxidase activity was revealed using the Super-
Signal West Pico Chemiluminescent Substrate (Pierce, Rockford,
IL, USA).
Determination of cell proliferation
Cell proliferation was determined by the Dojindo Cell Counting
Kit-8 (Dojindo, Gaithersburg, MD, USA). This assay is based on
the cleavage of the tetrazolium salt WST-8 by mitochondrial
dehydrogenase in viable cells (Aghdassi et al, 2007). Cells were
seeded in 96-well plates at a density of 5 10
3 cells in 100mlo f
culture medium and allowed to adhere overnight. After FXR siRNA
transfection or treatment with GS, 10ml of the tetrazolium
substrate were incubated at 371C for 1h and the absorbance at
450nm was measured.
Cell migration and invasion assay
Cell migration was assessed using 24-well inserts (Becton
Dickinson Labware, Franklin Lakes, NJ, USA) with 8-mm pores
according to the manufacturer’s protocol. After 24h of incubation,
the cells in the upper chamber were removed, and the cells were
fixed in ice-cold methanol, stained with Wright–Giemsa solution
(Polysciences, Warrington, PA, USA). Digital images were
obtained from the membranes, and cell areas were selected using
Scan Scope CS system (Aperio Technologies, Vista, CA, USA). The
migrating cells were quantified in five randomly selected fields at
 40 magnification in each membrane, and the average value was
defined as a migration or invasion index on three independent
membranes. Studies of invasion were performed as described
earlier, except that the membranes utilised were Matrigel-coated
invasion chambers (BD Biosciences, Bedford, MA, USA) that were
pre-hydrated in serum-free medium.
Enzyme-linked immunosorbent assay
Activation of NF-kB p65 was evaluated by enzyme-linked
immunosorbent assay (ELISA) (Active Motif, Carlsbad, CA,
USA) on nuclear extracts prepared with the nuclear extract kit
(Active Motif) according to the manufacturer’s instruction (de Haij
et al, 2003; Van Acker et al, 2007). The culture medium of the FXR
siRNA-transfected MIA-PaCa2 and PANC-1 cells assayed imme-
diately using commercially available VEGF ELISA kits (R&D
Systems).
Densitometric and statistical analysis
The bi-dimensional optical densities of FXR and b-actin proteins
on the films were quantified and analysed with Molecular Analyst
software (Bio-Rad, Hercules, CA, USA). Results are expressed as
mean±s.e.m. Group differences were statistically analysed using
the Student’s t-test. Survival curves were calculated by the
Kaplan–Meier method and differences were analysed by the log-
rank test. Correlations between FXR expression and LN metastasis
were analysed using the Mann–Whitney U-test. The Kaplan–
Meier method was used to generate survival curves, and
differences in probability values o0.05 were considered statisti-
cally significant.
RESULTS
Identification of genes differentially expressed between
pancreatic cancer tissues with and without LN metastasis
To minimise the number of falsely significant genes, genes in
which the signal-to-noise ratio was 43 in at least one sample and
the flag value was o500074 were filtered, leaving 15357 from the
original 30469 genes. Of the 15357 genes that were analysed on the
cDNA arrays, 184 genes (t-test, Po0.05) were differentially
expressed between pancreatic cancer tissues with LN metastasis
and those without LN metastasis. For the two groups we analysed,
only 58 genes were differentially expressed, with the difference
in signal intensity ratio 41.5 fold change. Of these genes sets,
15 genes were significantly upregulated in pancreatic cancer
tissues with LN metastasis compared with those without LN
metastasis. Table 2 contains complete lists of upregulated genes in
pancreatic cancer tissues with LN metastasis with the name,
description and chromosome location.
Validation of microarray data by real-time PCR
The differences in gene expression found by microarray analyses
were validated by real-time PCR. We chose genes that were
Table 2 Representative upregulated genes that were 4 1.5-fold expressed in pancreatic cancer tissues with lymph node metastasis
Probe_ID GB_accession Gene_symbol Gene_name Chromosome Fold (G II/G I)
200574 BC063443 LZIC Leucine zipper and CTNNBIP1 domain containing 1p36.22 3.06
207614 BC035654 FXR Farnesoid X receptor 12q23.3 2.63
101570 BC034048 SCAMP1 Secretory carrier membrane protein 1 5q13.3–q14.1 2.47
184216 BC027956 SULT1E1 Sulphotransferase family 1E, oestrogen-preferring, member 1 4q13.1 2.32
211511 BC052977 TNFRSF1B Tumour necrosis factor receptor superfamily, member 1B 1p36.3–p36.2 1.87
176066 BC022870 IFI44 Interferon-induced protein 44 1p31.1 1.74
223097 CR457297 SAV1 Salvador homolog 1 (Drosophila) 14q13–q23 1.71
189219 AL137764 SMAP1L Stromal membrane-associated protein 1 like 1p35.3–p34.1 1.70
130750 BC007932 C1orf165 Chromosome 1 open reading frame 165 1p33 1.68
169562 AF034780 EDG5 Endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 19p13.2 1.61
208619 BC038505 BAG4 BCL2-associated athanogene 4 8p11.23 1.57
197126 BX571754 SERPINB8 Serpin peptidase inhibitor, clade B (ovalbumin), member 8 18q21.3 1.56
188749 AK074638 ZCCHC8 Zinc-finger, CCHC domain containing 8 12q24.31 1.56
196290 BC005197 MBIP MAP3K12 binding inhibitory protein 1 14q13.2 1.54
107454 U90920 ARHGAP29 Rho GTPase-activating protein 29 1p22.1 1.50
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Among the genes, we evaluated the levels of expression of four
selected upregulated genes in pancreatic cancer tissues with LN
metastasis. The expression of LZIC, FXR, SCAMP1, and SULT1E1
was significantly higher in pancreatic cancer tissues with LN
metastasis than in pancreatic cancer tissues without LN metastasis
(Figure 1A). Although some variation concerning the degree of
regulation was observed, the data obtained with microarrays were
substantially confirmed for four selective genes by real-time PCR
(Figure 1B). In summary, microarrays together with real-time
PCR validation results clearly show that the expression of LZIC,
FXR, SCAMP1, and SULT1E1 were confirmed to be significantly
higher in pancreatic cancer tissues with LN metastasis than in
pancreatic cancer tissues without LN metastasis. These results are
representative for measurements accomplished with pancreatic
cancer tissues from three different experiments.
Immunohistological analysis of FXR expression
Among upregulated genes, FXR was selected for further investigation
because FXR, as a therapeutic target, has never been studied in
pancreatic cancer. To confirm the overexpression of FXR protein in
pancreatic cancer tissues with LN metastasis, we performed
immunohistochemical staining using anti-FXR antibody and vali-
dated overexpression of FXR protein in pancreatic cancer tissues with
LN metastasis (Figure 1C). For further analysis, the immunostaining
results were grouped into two categories. Those that exhibited 410%
immunoreactivity were classified as positive, whereas those with no
or o10% immunoreactivity was classified as negative. We observed
that 70.6% (12 of 17) of pancreatic cancer tissues with LN metastasis
were positive, of which staining was strong in 17.6%, moderate in
29.4%, and weak in 23.5% (Figure 1Cb). In pancreatic cancer tissues
without LN metastasis, positive expression of FXR was found in
17.6% (3 of 17) and negative in 82.4% (14 of 17) (Figure 1Ca). Overall,
staining was determined to be significantly stronger in pancreatic
cancer tissues with LN metastasis than in pancreatic cancer tissues
without LN metastasis for FXR expression (P¼0.0044). Overall
survival analysis using the Kaplan–Meier method revealed that the
prognosis of patients with tumours expressing positive FXR was
significantly poorer than that with tumours expressing negative FXR
(Figure 1D; P¼0.0227 by log-rank test). These findings are consistent
with the hypothesis that FXR-expressing cancers are somewhat more
aggressive than FXR-negative cancers, but only if other adverse
prognostic factors do not result in a rapid postoperative death.
Subsequently, we scanned several human pancreatic adenocarcinoma
cells for the expression of FXR.
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Figure 1 Gene expression analysis of selected upregulated genes and immunohistochemical expression of FXR in pancreatic cancer tissues with and
without LN metastasis. (A) Upregulated gene analysis between pancreatic cancer tissues with and without LN metastasis by real-time PCR. (B) Real-time
PCR validation of microarray data. For each sample, the amount of target and endogenous reference was determined from the appropriate standard curve.
The target amount was then divided by an endogenous reference (GAPDH) amount to obtain a normalised target value. The black columns represent the
mean of fold (Group II/Group I) values obtained in DNA microarray; the grey columns represent the mean of fold (Group II/Group I) values obtained in
real-time PCR; *Po0.05. (C) Overexpression of FXR in pancreatic cancer tissues with LN metastasis. The FXR intensity on tissues was evaluated
by immunohistochemical staining. (a) A representative negative staining in pancreatic cancer tissues without LN metastasis. Magnification,  200.
(b) A representative positive staining in pancreatic cancer tissues with LN metastasis. Magnification,  200. (D) Kaplan–Meier analysis of overall survival for
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proliferation and decreased cell migration and invasion
The baseline expression of FXR was determined in a panel of
human pancreatic cancer cell lines that included AsPC-1, Capan-1,
Capan-2, MIA-PaCa2, and PANC-1. The results showed that FXR
was frequently but differentially expressed in different human
pancreatic cancer cell lines (Figure 2A). HepG2 and MCF-7 cells
were used as positive controls for FXR expression (Bishop-Bailey
et al, 2004; Swales et al, 2006).
To determine whether or not FXR could be an effective therapeutic
target for pancreatic cancer, the effect of FXR siRNA on cell
proliferation was examined in MIA-PaCa2 and PANC-1 cells. The
efficacy of FXR siRNA for knock down of FXR mRNA and protein
was confirmed by real-time RT–PCR and western blotting,
respectively. We observed that both FXR mRNA and protein levels
were barely detectable in FXR siRNA-transfected cells compared with
siRNA control-transfected cells (Figures 2B and C).
The cell proliferation was determined by CCK-8, and the effect
of FXR siRNA on the proliferation of cancer cells is shown in
Figure 3A. We found that the downregulation of FXR expres-
sion inhibited cell proliferation in both pancreatic cancer cell lines.
The cell migration and invasion assay were performed with a
proliferation blocker (mitomycin C) to observe the effect of FXR
knockdown on the cell migratory or invasive potential without an
effect on cell proliferation. We found that downregulation of FXR
decreased cell migration (Figure 3B). Moreover, FXR siRNA-
transfected cells showed a low level of penetration through the
Matrigel-coated membrane compared with the control cells
(Figure 3C).
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activity and VEGF activity
The NF-kB signalling pathway is involved in cancer cell migration,
invasion, and metastasis processes. Therefore, we measured the
NF-kB DNA-binding activity in transfected pancreatic cancer cells.
Nuclear extracts from control and FXR siRNA-transfected
pancreatic cancer cells were subjected to analysis for NF-kB
DNA-binding activity, as measured by ELISA. It was found that
downregulation of FXR by siRNA transfection decreased NF-kB
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Giemsa. The relative-fold migration and invasion values of FXR siRNA-transfected cells was normalised against control siRNA-transfected cells and expressed as
percentages of the control, which was assumed to be 100%. Columns, mean of three independent experiments; bars, s.e.m. **Po0.01.
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regulated by NF-kB and has been reported to play an important
role in tumour progression (Zeng et al, 2003; Xiong et al, 2004).
To further explore whether FXR siRNA reduced VEGF activity,
we examined the levels of VEGF activity secreted in the culture
medium. We found that downregulation of FXR could lead to a
decrease in the levels of VEGF secreted in the culture medium
(Figure 4B).
GS inhibited cell proliferation and decreased migration
and invasion
We examined whether chemical inhibition of FXR affects cancer
cell proliferation, migration, and invasion. In both cell lines,
treatment with GS inhibited cell proliferation in a dose-dependent
manner (Figure 5A). GS (10mM) inhibited cell proliferation in
MIA-PaCa2 and PANC-1 cells compared to cells not treated
with GS that were observed after 72h. We also found that both
MIA-PaCa2 and PANC-1 cells decreased cell migration and
invasion by treatment with 10mM GS (Figures 5B and C).
GW4064 increased cell migration and invasion
To further confirm the role of FXR on cell migration and invasion,
cells were treated with GW4064, a selective and strong FXR agonist
(Maloney et al, 2000; Martinez-Fernandez et al, 2009). We
observed that both MIA-PaCa2 and PANC-1 cells increased cell
migration and invasion by treatment with 1mM GW4064 (Figures
6A and B). In addition, to explore a correlation with FXR target
gene, SHP (Goodwin et al, 2000), we performed RT–PCR. We
observed that SHP mRNA expression was very low in MIA-PaCa2
and PANC-1 cells compared with high levels detected in the HepG2
cell lines, used as a positive control. However, GW4064 did not
induce an increase of SHP mRNA in both cell lines (data not
shown).
DISCUSSION
Farnesoid X receptor is important in the progression of several
human cancers (De Gottardi et al, 2004; Silva et al, 2006; Swales
et al, 2006; Kim et al, 2007; Journe et al, 2008, 2009). However, the
expression of FXR and its role in human pancreatic cancer has not
been investigated previously. Our study showed, for the first time,
that FXR is highly expressed in human pancreatic adenocarcinoma
specimens and in five different human pancreatic cancer cell
lines tested, suggesting that FXR could be important in human
pancreatic cancer progression. Indeed, microarray analysis,
together with real-time PCR validation results, clearly showed
hat FXR was upregulated in pancreatic cancer tissues with LN
metastasis. We also found that FXR overexpression in pancreatic
cancer tissues with LN metastasis was associated with poor patient
survival. Therefore, these results suggest that FXR overexpres-
sion could be a useful prognostic marker for patients with
pancreatic cancer.
The role of FXR in growth regulation, apoptosis, and cancer is
still controversial. Several studies have established both positive
and reciprocal correlations between FXR expression and cancer
(De Gottardi et al, 2006; Kim et al, 2007; Journe et al, 2008; Modica
et al, 2008; Maran et al, 2009). However, the precise role and
mechanism of FXR for tumour cell proliferation, migration, and
invasion remains unclear. In this study, we have shown the
following: (a) downregulation of FXR by siRNA inhibited cell
proliferation and decreased migration and invasion; (b) down-
regulation of FXR reduced NF-kB DNA-binding activity and VEGF
activity; (c) the FXR antagonist GS inhibited cell proliferation and
decreased migration and invasion; and (d) the FXR agonist
GW4064 increased cell migration and invasion. Taken together,
these results suggest that the downregulation of FXR is an effective
approach for the inactivation of FXR and downregulation of its
target genes, such as NF-kB and VEGF, resulting in the inhibition
of invasion and metastasis of pancreatic cancer cells.
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sAlthough the underlying mechanism is not clear, FXR may be
involved in regulating cell proliferation, migration, and invasion
by multiple mechanisms in several cancer types. In breast cancer,
significant correlations have been observed between the expression
of FXR and proliferation markers (Ki-67 and several other
proliferation markers), including TopoII and c-myc transcription
factors (Journe et al, 2008). It has been reported that GS decreases
the expression of gene products involved in proliferation (cyclin
D1 and c-myc) by inhibition of NF-kB and IkBa kinase activation
in human cells derived from lung carcinoma and leukaemia
(Shishodia and Aggarwal, 2004). A recent study shows that Z-GS
blocks the proliferation of human tumour cell types, including
leukaemia, head and neck carcinoma, multiple myeloma, lung
carcinoma, melanoma, breast carcinoma, and ovarian carcinoma
by arresting the cells in the S-phase of the cell cycle (Shishodia
et al, 2007). Similar observations have been made in other
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smalignancies. A previous study has shown that bile acid-sensitive
PCmsrc and HCT-8/E11 human colorectal cancer cell lines
expressed FXR, and bile acids stimulated invasion through
activation of multiple oncogenic signalling (Debruyne et al,
2002). In addition, the FXR antagonist, Z-GS, prevented the
migration of metastatic human breast cancer MDA-MB-231 cells
(Silva et al, 2006).
Indeed, we found that transfection with FXR siRNA and treatment
with GS resulted in a marked reduction in cell proliferation,
migration, and invasion, suggesting that FXR expression promote
tumour progression in pancreatic cancer. Moreover, this study
revealed that FXR activation by GW4064 increased cell migration and
invasion. On the basis of our results, we could speculate FXR as a
tumour progressor in pancreatic cancer.
However, several other studies showed FXR as a tumour
suppressor rather than a tumour progressor. Modica et al (2008)
have shown that loss of FXR in mouse models of intestinal
tumorigenesis results in early mortality and increased tumour
progression. Farnesoid X receptor deficiency has been shown to
increase adenocarcinoma size in the small intestine of the APC
min
mice and increase the prevalence and size of AOM-induced
adenocarcinoma in the colon (Maran et al, 2009).
Nuclear factor-kB activation is closely involved in the progres-
sion of pancreatic cancer due to its ability to increase expression of
angiogenic factors including VEGF, and promote the migration
and invasion of pancreatic cancer cells (Yebra et al, 1995; Xiong
et al, 2004).
Angiogenesis has been known to play an important role in the
development of tumour growth and LN metastasis. Vascular
endothelial growth factor potently increases vascular permeability
and promotes the formation of new blood vessels in tumour, and
thus is regarded as the main growth-stimulatory factor in the
tumour-related angiogenesis (Lequerica-Fernandez et al, 2007).
The prognostic value of high expression of VEGF has been shown
in various types of human tumours (Arinaga et al, 2003; Tamura
et al, 2004; Lequerica-Fernandez et al, 2007). It has been reported
that pancreatic cancer patients with LN metastasis have higher
serum concentrations of VEGF when compared with those without
LN involvement (Karayiannakis et al, 2003). High level of VEGF
expression significantly correlated with advanced tumour stage
and LN metastasis (Sun et al, 2007). Investigations by other
laboratories have shown that VEGF promotes migration and
invasion of pancreatic cancer cells (Fujioka et al, 2003; Wey et al,
2005). The results of these investigations suggested a trend toward
an association between expression of VEGF and LN metastasis.
In agreement with our proliferation, migration, and invasion
data, we found that the downregulation of FXR inhibited
NF-kB DNA-binding activity. Moreover, we found a significant
reduction of VEGF secretion on the culture medium of pancreatic
cancer by the downregulation of FXR using siRNA transfection.
It is well accepted that the expression of VEGF is regulated
by NF-kB (Huang et al, 2001; Shi et al, 2001). Therefore, these
results suggest that downregulation of FXR could inhibit cancer
cell proliferation, migration, and invasion partly through the
downregulation of NF-kB and its target gene, VEGF. However,
further in-depth studies are needed to ascertain the precise
molecular regulation of FXR and NF-kB and their cross-talks in
elucidating the role of FXR in cell proliferation, migration, and
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Figure 6 Effect of FXR agonists GW4064 on pancreatic cancer cell migration and invasion. DMSO, control. (A, B) MIA-PaCa2 and PANC-1 cells were
treated with 1mM GW4064 for 48h. Cells were placed in serum-free culture media and added into the upper compartment of a migration or invasion
chamber. After 24h, cells in the upper chamber were removed and cells that had migrated (A) or invaded (B) onto the lower surface of the membrane
were fixed and stained with Wright–Giemsa. The relative-fold migration and invasion values of GW4064-treated cells were normalised against
DMSO-treated cells and expressed as percentages of the control, which was assumed to be 100%. Columns, mean of three independent experiments; bars,
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pancreatic cancer.
In conclusion, our findings show, for the first time, that FXR
overexpression in pancreatic cancer tissues with LN metastasis is
associated with poor patient survival. Furthermore, we presented
experimental evidence that strongly supports the role of FXR
downregulation as antitumour and antimetastatic mechanisms in
pancreatic cancer. Therefore, downregulation of FXR could be an
effective approach for the inactivation and reduction of NF-kB and
its target gene, VEGF, which is likely to result in the inhibition of
migration, invasion, and metastasis of pancreatic cancer.
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